We could be getting a peak at some early stage compound(s) in the pipeline at AASLD. The PR hinted at it and I am glad to see one of the analysts followed up on it (I thought I was the only nit-picky person for wording to pick up hints).
Here is the wording. I believe it was Brian Abrahams who asked about it. Submitted several abstracts for possible presentation at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) to be held October 31 - November 4, 2008 in San Francisco, including but not limited to data on ITMN-191
Market Data 
Markets 
AI
